Marinomed Biotech AG Completes Successful Capital Increase

On April 13, 2026, Marinomed Biotech AG, based in Korneuburg, Austria, announced the successful completion of its capital increase against cash contribution. The company raised gross proceeds of approximately EUR 2.23 million, exceeding its target of EUR 2 million. This was achieved through a rights offering to existing shareholders, securing 33,322 new shares, and a private placement of an additional 125,717 shares at EUR 14 each. A total of 159,039 new shares were issued.

CEO Andreas Grassauer expressed satisfaction with the results, noting the strong investor confidence and the assurance of financial resources needed for future milestones. This funding aims to cover liquidity needs and support ongoing negotiations for marketing Marinomed's flagship products, Budesolv and Tacrosolv. Trading of the new shares on the Vienna Stock Exchange is anticipated to commence on April 20, 2026.